2017. Dupilumab in Moderate-to-Severe Atopic Dermatitis: Pooled Efficacy Results from Two Identically Designed Randomized Phase 3 Trials (SOLO 1 & 2). SKIN The Journal of Cutaneous Medicine. 1, 3.1 (Oct. 2017), s38. DOI:https://doi.org/10.25251/skin.1.supp.37.